dimebon blowout, page-17

"Thus, a result might be highly statistically significant, (i.e the differences observed are "real") yet be so small as to be of no pratcical relevance to real patients."
The difference most Alzheimers trials are hoping for are progression versus non progression.
To see an improvement in patients, as Prana saw in their Phase 2a trial on Alzheimers patients is fantastic, and then to be able to prove the improvement in a properly run blinded trial with statistically significant improvements emerging once the trial info is unblinded, is really something in this terrible disease.
To quote the CEO after the trial results, "the patients were getting better"
Alois, why are you so negative when Prana are the ONLY Alzheimers trial for a disease modifying drug to show a statistical significant improvement in any alzheimers field. They have since demonstrated in the lab why it would show an improvement, and trending in the trial is encouraging that a longer trial would show better results.
There are still 15,000 shorts (150,000 Aus shares)outstanding. Thats not you is it old buddy?